MESA LABORATORIES INC /CO/

Mesa Laboratories reported Q1 2026 revenue of $60.1 million, a modest increase from the prior year. Despite a significant rise in operating income to $7.0 million, net income and diluted EPS saw substantial declines, reaching $2.8 million and $0.49 respectively. The company also reduced its revolving line of credit balance and settled a previously disclosed litigation.

Mesa Laboratories, Inc. announced it will release its first fiscal quarter (1Q27) financial results, for the period ended June 30, 2026, after market close on Monday, August 10, 2026. The company will also host an earnings conference call on the same day at 4:30 p.m. Eastern Time to discuss the results in detail. The call will conclude with a Q&A session for analysts, and a replay will be available for 45 days.

Mesa Laboratories, Inc. announced the appointment of Dr. Siddhartha Kadia as its new President and Chief Executive Officer in April 2026, succeeding Gary Owens. The company also detailed the agenda for its 2026 Annual Meeting of Shareholders, scheduled for September 8, 2026. Shareholders will vote on the election of seven director nominees, the ratification of Baker Tilly US, LLP as the independent auditor, and an advisory vote on executive compensation. The filing highlights the company's commitment to strong corporate governance and a performance-based executive compensation structure.

Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. This dividend will be paid on September 15, 2026, to shareholders who are on record as of the close of business on August 31, 2026.

Mesa Laboratories, Inc. announced the appointment of Lyndsey Crennen as its new Chief Accounting Officer, effective upon the execution of her employment agreement. Crennen, with over 20 years of experience, has been with Mesa since 2018, most recently serving as Corporate Controller. Her new role comes with an annual base salary of $325,000, eligibility for a 40% annual bonus, and a long-term incentive award target of $300,000.

Mesa Laboratories Inc. filed its annual report on Form 10-K, detailing its business operations across four segments: Sterilization and Disinfection Control, Biopharmaceutical Development, Calibration Solutions, and Clinical Genomics. The report highlights the recent acquisition of GKE, which has been integrated into the Sterilization and Disinfection Control division. The company also provided updates on its backlog, customer concentration, and human capital, noting a decrease in backlog and a stable employee headcount with reduced turnover.

Mesa Laboratories reported mixed results for its fourth fiscal quarter and full fiscal year 2026. For Q4, revenues increased 2.6% to $63.7 million, while the company posted a GAAP net loss of $4.1 million. Full fiscal year 2026 revenues grew 3.4% to $249.1 million, with GAAP net income of $6.7 million. The company also repaid $14.7 million in debt during Q4, reducing its net leverage ratio to 2.11, and expects overall revenues to return to positive core organic growth in 1Q27.

Mesa Laboratories reported a 3.4% increase in full fiscal year 2026 revenues to $249.1 million and a 13.3% rise in operating income to $18.5 million. For the fourth quarter of fiscal year 2026, revenues grew 2.6% to $63.7 million and operating income surged 87% to $2.7 million. The company repaid $14.7 million of debt in 4Q26, reducing its Total Net Leverage Ratio to 2.11. Challenges in the Biopharmaceutical Development division due to commercial execution and export controls were noted, while the Sterilization and Disinfection Control division showed strong growth.

Mesa Laboratories, Inc. announced that it will release its financial results for the fourth quarter and the fiscal year ended March 31, 2026. The press release is scheduled for Wednesday, May 27, 2026, at approximately 6:00 A.M. Eastern Time.